EUVIMEDEUVIMED entdecken
Crossref

Artificial intelligence in prognostication and treatment response modeling in advanced hepatocellular carcinoma

Babu Lal Meena, Bijaylaxmi Behera, Omkar S Rudra, Deepti Sharma

Artificial Intelligence in Gastroenterology · 18.08.2026 · 7 (2)

DOI: 10.35712/aig.120311 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Artificial Intelligence in Gastroenterology, online erschienen am 18.08.2026. Verfasst von Babu Lal Meena und 3 weiteren Autor:innen. Die Arbeit nennt 52 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advanced hepatocellular carcinoma (HCC) presents a dual challenge of tumor progression and underlying hepatic dysfunction, resulting in substantial heterogeneity in survival and treatment response. Artificial intelligence (AI) has been increasingly applied to address limitations of conventional stage-based systems; however, its impact on clinical decision-making remains uncertain. We conducted a narrative critical review of primary validation studies and high-quality systematic reviews (2020-2026) evaluating AI-based survival prediction and treatment response modeling in advanced HCC. We focused on methodological rigor, external and temporal validation, calibration, causal inference, and translational readiness. Several retrospective studies report improved discrimination for radiomic, deep learning, and multimodal machine learning models compared with conventional frameworks such as Barcelona Clinic Liver Cancer staging and albumin-bilirubin grade. Absolute area under the receiver operating characteristic curve improvements of approximately 0.14-0.40 have been reported in selected cohorts. These models improve intra-stage risk stratification and have the potential to predict response to systemic and locoregional therapies. However, most studies remain retrospective and focus primarily on prognostic rather than predictive modeling. External validation, calibration assessment, and competing-risk adaptation are inconsistently reported, and causal approaches to estimate treatment-effect heterogeneity are rarely used. Evidence demonstrating improvement in therapeutic allocation or patient-centered outcomes remains limited. AI-based modeling in advanced HCC offers improved risk stratification, yet improved discrimination metrics alone do not establish clinical utility. Prospective validation, causal inference frameworks, standardized reporting, and demonstration of decision impact are essential prerequisites for clinical integration. Without such rigor, AI may remain technologically sophisticated yet clinically unproven.

Zitieren

APA

Meena, B. L., Behera, B., Rudra, O. S., & Sharma, D. (2026). Artificial intelligence in prognostication and treatment response modeling in advanced hepatocellular carcinoma. Artificial Intelligence in Gastroenterology, 7(2). https://doi.org/10.35712/aig.120311

Vancouver

Meena BL, Behera B, Rudra OS, Sharma D. Artificial intelligence in prognostication and treatment response modeling in advanced hepatocellular carcinoma. Artificial Intelligence in Gastroenterology. 2026;7(2). doi:10.35712/aig.120311

BibTeX
@article{Meena2026,
  author = {Meena, Babu Lal and Behera, Bijaylaxmi and Rudra, Omkar S and Sharma, Deepti},
  title = {Artificial intelligence in prognostication and treatment response modeling in advanced hepatocellular carcinoma},
  journal = {Artificial Intelligence in Gastroenterology},
  year = {2026},
  volume = {7},
  number = {2},
  doi = {10.35712/aig.120311}
}
Kostenlos starten →